Salmeterol dry-powder inhalation - GlaxoSmithKline
Alternative Names: Salmeterol xinafoate dry-powder inhalation - GlaxoSmithKline; Serevent Accuhaler; Serevent Diskhaler; Serevent Diskus; SN 408 dry-powder inhalation - GlaxoSmithKlineLatest Information Update: 24 Oct 2021
At a glance
- Originator GlaxoSmithKline
- Developer GSK
- Class Antiasthmatics; Antibronchitics; Bronchodilators; Ethanolamines; Phenethylamines; Small molecules
- Mechanism of Action Beta 2 adrenergic receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Asthma; Chronic obstructive pulmonary disease
Most Recent Events
- 04 Mar 2004 Serevent® 50 Diskus® has been approved in Japan for Asthma and Chronic obstructive pulmonary disease
- 06 May 2003 Launched for Asthma in Australia (Inhalation)
- 06 Aug 2002 Launched for Chronic obstructive pulmonary disease in Japan (Inhalation)